The transient receptor potential vanilloid 3 (TRPV3) channel is a heat-sensitive ion channel, which is predominantly expressed in keratinocytes. TRPV3 channels are involved in numerous physiological and pathophysiological processes within the skin, including cutaneous nociception, temperature sensation and development of itch. The role of TRPV3 channels in such processes is poorly understood; therefore, the establishment of selective modulators of TRPV3 channels is highly desirable.
Introduction
The transient receptor potential vanilloid 3 (TRPV3) channel is a calcium-permeable cation channel, which is activated by innocuous warm temperatures above 39°C (Peier et al., 2002) . Apart from heat, TRPV3 channels can be stimulated by a plethora of different chemical stimuli including synthetic 2-aminoethoxydiphenyl borate (2-APB) as well as various natural compounds derived from plants, such as the monoterpenes carvacrol, thymol, camphor and eugenol (reviewed in Huang and Chung, 2013) . In experimental assays, 2-APB is often used to elicit TRPV3 activity, but it is far from being specific for TRPV3. Besides its action as an inhibitor of inositol 1,4,5-trisphosphate receptors, 2-APB modulates many other TRP channels by either activating (TRPV1, TRPV2, TRPV3), or inhibiting (TRPC1, TRPC3, TRPC5, TRPC6, TRPV6, TRPM3, TRPM7, TRPM8) channel activity.
Although TRPV3 channels are clearly activated by warm temperatures in vitro, TRPV3-deficient mice did not display clear deficits in thermosensation (Huang et al., 2011) . A reduced response to acute noxious heat and innocuous heat has been demonstrated in some but not all studies examining TRPV3 knockout mice, possibly depending on the genetic background of the animals (Moqrich et al., 2005; Huang et al., 2011) .
There is emerging evidence that TRPV3 contributes to important processes in keratinocyte physiology and skin disease (Nilius and Biro, 2013) . Keratinocytes as well as epithelial cells of the nose and tongue display a high expression of TRPV3 across species. TRPV3 may form signalling complexes with the EGF receptor (EGFR) in a way that activation of the EGFR increases TRPV3 activity (Peier et al., 2002; Xu et al., 2006; Cheng et al., 2010) . TRPV3 is also present in cells surrounding the hair follicles, inhibiting hair follicle growth and cycling (Borbiro et al., 2011) . Moreover, TRPV3 is essential for maintaining the formation of the skin barrier, and gain-of-function mutations of TRPV3 are linked to congenital Olmsted syndrome, which is characterized by alopecia and mutilating palmoplantar keratoderma (Cheng et al., 2010; Lin et al., 2012) . The expression of over-active TRPV3 channels leads to elevated intracellular calcium levels, ultimately resulting in an increased apoptosis of keratinocytes followed by skin hyperkeratosis (Borbiro et al., 2011; Radtke et al., 2011) . Highly active TRPV3 channels may cause the development of pruritus and an increased scratching behaviour in mice, possibly via the release of pro-inflammatory agents, pruritogens and increased local nerve sprouting, making TRPV3 a novel and promising target for the treatment of itch (Yoshioka et al., 2009; Yamamoto-Kasai et al., 2013) .
Given the lack of TRPV3 expression in peripheral neurons, it is still not clear how sensory TRPV3-mediated signals in keratinocytes are further processed. It is suggested that the release of ATP as a signalling molecule links the communication between keratinocytes and neurons (Mandadi et al., 2009) . Apart from keratinocytes, TRPV3 expression has also been detected in other tissues, such as the brain, but to a much lower extent and, up to now, its specific function in such areas still has to be determined.
Here, we describe a novel target of several COX-2-selective inhibitors that is independent of their action on COX-2. We showed that the activity of recombinantly expressed TRPV3 channels as well as native TRPV3 in a mouse keratinocyte cell line is strongly modulated by the antiphlogistic and analgesic drugs celecoxib and deracoxib. Their action on TRPV3 channels is direct and depends on the stimulus that is used to activate TRPV3, as they potentiated 2-APB-and heatevoked, but not carvacrol-evoked, TRPV3 activity. and m308 k cells were plated onto poly-L-lysine-coated glass coverslips 24-48 h prior to measurements. Cells were loaded with 2 μM fura-2 AM (Molecular Probes, Eugene, USA) for 30 min in a HEPES-buffered solution (HBS; 10 mM HEPES, 132 mM NaCl, 6 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 5 mM glucose), washed in HBS buffer and subjected to the experimental conditions. Analysis of changes in [Ca 2+ ] i was performed as described previously (Lenz et al., 2002) . To conduct the initial compound screen and to generate concentration-response curves, cell suspensions were loaded with 5 μM fluo4/AM (Invitrogen, USA) in HBS solution for 30 min, washed with HBS solution and dispensed into 384-well microtitre plates (10 000 cells per well; Corning, MA, USA). Fluorescence was recorded using a custom-made fluorescence imaging plate reader, corrected for background signals and expressed as F/F 0 . The Spectrum Collection (MicroSource, Gaylordsville, CT, USA) compound library was used to conduct a medium-throughput compound screen.
Methods

Cell
Patch clamp measurements
Cells were seeded onto glass coverslips prior to the experiments. Whole-cell patch clamp recordings were conducted at room temperature if not stated otherwise. Currents were recorded using the Multiclamp 700B amplifier together with the digitizer Digidata 1440A under the control of the pClamp10 software (Molecular Devices, Sunnywale, CA, USA). The extracellular solution consisted of 140 mM NaCl, 5 mM CsCl, 2 mM MgCl 2 , 1 mM CaCl 2 and 10 mM HEPES (adjusted to pH 7.4 with NaOH). Pipettes were filled with intracellular solution composed of 140 mM CsCl, 4 mM MgCl 2 , 10 mM EGTA and 10 mM HEPES (adjusted to pH 7.2 with CsOH). For inside-out measurements, intra-and extracellular solution contained the following: 140 mM NaCl, 10 mM glucose, 0.5 mM EGTA and 10 mM HEPES (adjusted to pH 7.2 with NaOH). Series resistances were <10 MΩ and were compensated by 75%. Whole-cell currents were filtered at 3 kHz (four-pole Bessel filter) and sampled at 10 kHz. Slow 1 s voltage ramps ranging from V h = À70 to +70 mV were applied every 2 s. Current densities were normalized to cell capacitance and are depicted as pA/pF. For controlling the temperature of the bath solution, an inline solution heater (TC-324, Warner instruments, Hamden, CT, USA) was used together with a thermistor electrode placed directly near the recorded cell.
Statistical analysis
Data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Blinding was not performed for this study as all experiments revealed strict quantitative data. Cell culture dishes were randomly assigned to various treatments. The results are depicted as mean ± SEM. Curve fitting for determination of EC 50 values was performed using the Hill function:
, where k is the concentration of drug yielding a half-maximal effect, n H characterizes the slope and min and max are the minimal and maximal asymptotes respectively. Normalization of individual datasets was performed for determination of EC 50 values for celecoxib and deracoxib in HEK TRPV3-CFP and m308 k cells to reduce variability in baseline between independent experiments. The numbers of independent experiments are stated in the figure legends. Levene's test was performed to evaluate equality of variances of data. When necessary, data were logor square root-transformed prior to analysis. Current values at negative holding potentials were multiplied by À1 before transformation. Statistical significance between two normally distributed data groups was assessed using Student's paired t-test or ANOVA analysis followed by a Tukey significance test. Post hoc tests were run only if F achieved P < 0.05 and there was no significant inhomogeneity. Statistical significance was achieved at P < 0.05. Statistical analysis was performed using OriginPro 8G (OriginLab Corporation Northhampton, MA, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
We screened a compound library (Spectrum Collection, MS Discovery), consisting of approved pharmaceutical drugs and natural products in order to identify compounds that modulate TRPV3 channels. To this end, an HEK TRPV3-CFP cell line was generated, stably expressing CFP-tagged mouse TRPV3 ( Figure 1A ). A microtiter-based calcium assay, utilizing the calcium indicator dye fluo-4, was used to determine concentration response curves for two different agonists. A concentration-dependent rise in [Ca 2+ ] i was revealed with EC 50 values of approximately 45 μM for the 2-APB-and 157 μM for the carvacrol-induced activation of TRPV3 (Figure 1B, C; filled symbols). These values are in line with previous reports, rendering the HEK TRPV3-CFP cell line a validated tool for identifying TRPV3-modulating compounds. However, parental HEK293 cells also responded to high concentrations of both agonists (>125 μM) with a non-specific increase in the fluorescence, which is presumably caused by an unspecific release of calcium from internal stores (Figure 1B , C; open symbols) Therefore, for further experiments in HEK TRPV3-CFP cells, a sub-maximal agonist concentration of ≤100 μM 2-APB was chosen to limit the occurrence of non-specific calcium signals in calcium assays.
In the screening approach, we identified deracoxib as a novel TRPV3 modulator, which strongly potentiated the 2-APB-induced calcium signal in HEK TRPV3-CFP cells. We next performed fura-2-based calcium assays on single cells. When HEK TRPV3-CFP cells were challenged with 100 μM 2-APB, they responded with a TRPV3-mediated calcium influx, which was further increased after addition of deracoxib ( Figure 2A) . Control experiments using the parental HEK293 cell line did only reveal minor increases in [Ca 2+ ] i after 2-APB application, which were not affected by the addition of deracoxib (Figure 2 C). We next tested whether other COX-2-selective inhibitors, which share a similar chemical structure, also affect TRPV3 activity. To this end, we evaluated the effect of celecoxib, valdecoxib, parecoxib, rofecoxib and etoricoxib on TRPV3 channels. Celecoxib, which shares the most common structural features with deracoxib, for example, its fluoromethyl group, also exhibited a high efficacy in potentiating TRPV3 channels in the presence of 2-APB ( Figure 2B ). Valdecoxib and parecoxib did also significantly enhance 2-APB-mediated TRPV3 activation but to a much lesser extent compared with deracoxib and celecoxib. In contrast, etoricoxib did not affect TRPV3 channels in the calcium assay ( Figure 2D ). Rofecoxib exhibited intrinsic fluorescence when added in the fura-2-based calcium assay and was not further evaluated in this assay but only in electrophysiological recordings, in which it affected TRPV3 to a minor degree. Without a preceding activation by 2-APB, deracoxib was ineffective in activating TRPV3 channels and did not cause a calcium influx in HEK293 control cells. Also, celecoxib alone did only elicit very minor responses in HEK TRPV3-CFP cells and HEK293 control cells ( Figure 2E ). As TRPV3 is endogenously expressed in keratinocytes and in the keratinocyte-derived mouse 308 k cell line (Grubisha et al., 2014) , we used m308 k cells to test whether celecoxib and deracoxib also modulate endogenously expressed TRPV3 channels in a similar way. A 2-APB-and carvacrol-induced increase in [Ca 2+ ] i could be determined by fluo-4-based FLIPR assays. For carvacrol but not for 2-APB, a saturation in the fluorescence signal was achieved at concentrations above 500 μM (EC 50 = 189.9 ± 22.5 μM; n = 5). For 2-APB, no EC 50 values could be obtained ( Figure 3A , B) as saturation was not achieved. In order to stimulate endogenous TRPV3 channels in m308 k cells, higher agonist concentrations were necessary compared with HEK TRPV3-CFP cells. The addition of 300 μM 2-APB elicited only small increases in [Ca 2+ ] i in the BJP S Spyra et al.
majority of the cells ( Figure 3C ). However, celecoxib and deracoxib potentiated 2-APB-evoked calcium signals by a factor of two, while valdecoxib, etoricoxib and parecoxib did not enhance 2-APB-mediated [Ca 2+ ] i ( Figure 3D ).
The EC 50 values for the potentiation of the 2-APB-evoked signal by deracoxib and celecoxib were determined by FLIPR measurements using HEK TRPV3-CFP and m308 k cells (Figure 4 ). We applied a constant concentration of 2-APB (10 and 100 μM 2-APB for HEK TRPV3-CFP and m308 k cells, respectively), which caused a submaximal activation of TRPV3. In HEK TRPV3-CFP cells, celecoxib was the most potent compound with an EC 50pot of 6.3 ± 1.6 μM, followed by deracoxib (EC 50pot = 19.2 ± 2.2 μM). Similar potencies were calculated for the potentiation of endogenously expressed TRPV3 in the m308 k cell line (EC 50pot = 7.0 ± 2.7 μM for celecoxib and EC 50pot = 11.9 ± 5.6 μM for deracoxib). At 100 μM, the concentration-response curves for celecoxib showed a drop, indicating that at very high concentrations, celecoxibmediated potentiation is less pronounced and might overlap with a block of channel activity. We therefore did not include this data point for curve fitting.
In contrast to many other ion channels, which desensitize during agonist application, TRPV3 activity strongly increases during repetitive stimulation, independent of the stimulus (e.g. chemical ligands, temperature) (Peier et al., 2002; Xu et al., 2002) . We next wanted to determine whether the two most potent compounds, celecoxib and deracoxib, also potentiate TRPV3 currents in whole-cell patch clamp recordings.
As expected, HEK TRPV3-CFP cells responded to the application of 100 μM 2-APB, with an outwardly rectifying current, reversing close to 0 mV ( Figure 5A, B) . The addition of celecoxib (20 μM) induced a strong and long-lasting potentiation of 2-APB-induced TRPV3 currents, which was reversible upon washout. The inward current (V h = À70 mV) increased by a factor >100 and the outward current (V h = +70 mV) by a factor of 15. Also, deracoxib evoked an instant and strong potentiation of TRPV3 inward and outward currents ( Figure 5D ). Valdecoxib, etoricoxib, parecoxib and rofecoxib (20 μM) did affect TRPV3 gating to a much lesser extent ( Figure 5C ). To test whether the current potentiation is a direct effect of an interaction between the compound and the TRPV3 channel or whether it relies on the involvement of 
Figure 4
Determination of the potency of celecoxib-and deracoxib-induced increase of TRPV3 activity in HEK TRPV3-CFP (A) and m308 k (B) cells. TRPV3 was activated with a constant concentration of 10 μM 2-APB (A; HEK TRPV3-CFP ) or 100 μM 2-APB (B; m308 k), followed by the addition of celecoxib or deracoxib at different concentrations. Data depict mean of several independent experiments for each condition (HEK TRPV3-CFP n = 5; m308 k n = 6). EC 50 values were calculated by subsequent non-linear curve fitting with the Hill equation. The data points for celecoxib at 100 μM are shown in the graph but were not included for curve fitting. intracellular components, we next conducted single channel measurements in isolated inside-out patches. In this configuration, the addition of 1 μM 2-APB to the bath solution elicited infrequent and short openings of the TRPV3 channel ( Figure 5D , upper trace). The single channel amplitude of 13.3 pA at À70 mV ( Figure 5E ; reflecting a conductance of 190 pS) is in line with reported values for TRPV3 channels in magnesium-free buffer (Luo et al., 2012) . However, the addition of 50 μM deracoxib caused an approximately fourfold increase in the open probability of TRPV3 channels (NPo) (NPo 2-APB : =0.18 ± 0.22 vs. NPo 2-APB+deracoxib : =0.74 ± 0.39; P < 0.05) but did not affect the single channel current amplitude (2-APB-induced 13.3 ± 1.8 pS vs. 2-APB + deracoxibinduced 14.1 ± 1.1 pS; Figure 5D -F). Endogenous 2-APB-elicited whole-cell currents in the m308 k cell line were much smaller compared with TRPV3 currents in the HEK TRPV3-CFP cell line ( Figure 6A , B) but clearly exhibited TRPV3-like properties. Again, the application of celecoxib (10 μM) caused a robust potentiation of both inward and outward currents, indicating that also native TRPV3 channels are sensitive to celecoxib.
Besides 2-APB, a number of other non-specific TRPV3 activators have been described, including the phenolic monoterpenes carvacrol, thymol and camphor, which presumably exhibit a distinct mechanism of activation compared with 2-APB (Hu et al., 2009; Sherkheli et al., 2013) . As an example for the monoterpene-induced TRPV3 activators, we used carvacrol and performed electrophysiological recordings to determine whether the carvacrol-induced TRPV3 current can also be augmented by celecoxib. In HEK TRPV3-CFP , 500 μM carvacrol elicited currents, which strongly increased with repeated cycles of simulation. As a plateau of carcvacrol-induced TRPV3 currents was often not achieved and long-lasting exposure to carvacrol led to an irreversible TRPV3 activation or a loss of the patch, we examined the effect of celecoxib in a configuration, in which we first challenged the cells with a mixture of carvacrol and celecoxib, followed by a washout of celecoxib ( Figure 7A,  B) . Interestingly, the presence of celecoxib did not potentiate the carvacrol-activated TRPV3 currents when added at a concentration of 10 and 50 μM but rather led to an inhibition of TRPV3 currents (Figure 7A-C) , indicating that the potentiation of TRPV3 by celecoxib is dependent on the stimulus used. HEK293 control cells did not reveal changes of the basal current in response to 500 μM carvacrol or 50 μM celecoxib ( Figure 7D ).
Despite extensive research, an endogenous ligand of TRPV3 has not been identified, yet. TRPV3 belongs to the thermo-sensitive TRP channels and is activated by innocuous warm temperatures starting between 31-39°C. We elicited temperature-activated TRPV3 currents in HEK TRPV3-CFP cells at 40°C. In line with previous reports, the temperature-gated TRPV3 currents displayed a strong sensitization towards repeated heat stimuli (Xu et al., 2002) . To test whether also heat-evoked TRPV3 responses are sensitive to sensitization, we applied celecoxib (10 μM) at a constant temperature of 40°C. As evident from the current trace, the addition of celecoxib caused a strong potentiation of heat-evoked TRPV3 currents by a factor of 2-3 ( Figure 7E, F) .
Discussion
COX-2 selective inhibitors also referred to as coxibs are widely used as analgesics and anti-inflammatory agents as they reduce prostaglandin synthesis via a selective inhibition of COX-2. They are used for treating inflammatory rheumatoid arthritis or for relieving post-operative pain (Reitz et al., 1994; FitzGerald & Patrono, 2001) . Interestingly, celecoxib has also been shown to be effective in the chemoprevention of non-melanoma skin cancer, and formulations have been developed to topically apply celecoxib to the skin (Pentland, 2002; Elmets et al., 2010) . Apart from their action on COX, several COX-independent targets for coxibs, most notably of celecoxib, have been identified. They include several voltage-activated ion channels, which are modulated by celecoxib. For example, Na + currents (Park et al., 2007; Frolov et al., 2011) , L-type calcium channels (Zhang et al., 2007; Brueggemann et al., 2009) , Kv2.1 (Frolov et al., 2010) , Kv1.5, Kv4.3 and Kv7.1 (Macias et al., 2010) and human eag-related gene potassium channels (Frolov et al., 2011) are all inhibited by celecoxib. In contrast, celecoxib increases Kv7.2-5 currents (Brueggemann et al., 2009; Du et al., 2011) . A direct
Figure 6
Celecoxib-mediated potentiation of 2-APB-stimulated TRPV3 currents in m308 k cells. (A) Time course of a representative whole-cell patch clamp recording with repetitive application of 2-APB (100 μM) and celecoxib (10 μM) as indicated by the bars. Data were extracted from voltage ramps ranging from À70 to +70 mV. (B) Statistical evaluation of five independent experiments such as in (A) (*P < 0.05).
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action of coxibs on TRP channels have, to our knowledge, not been described so far. TRPV3 is mainly expressed in the skin. In general, it is believed that a massive activation of TRPV3 in keratinocytes causes elevated concentrations of [Ca 2+ ] i , leading to a Ca 2+ overload and subsequent cell death (Borbiro et al., 2011; Radtke et al., 2011) . This might explain the hairless phenotype and dermatitis in rodent strains, which express a gainof-function variant of TRPV3 (Yoshioka et al., 2009) . TRPV3 also contributes to the release of pro-inflammatory mediators and pro-nociceptive mediators, such as TGF-α, PGE 2 , substance P and ATP (Mandadi et al., 2009; Huang et al., 2008) . Accordingly, TRPV3-selective antagonists may be useful for the development of drugs targeting itch and other skinrelated conditions, such as Olmsted syndrome. We here report that the drug celecoxib potentiates heatand 2-APB-induced TRPV3 currents. As TRPV3 is highly expressed in keratinocytes, it might represent a target for celecoxib, when topically applied or, to a lesser extent due to low peak plasma concentration, when applied systemically. Studies have evaluated steady-state plasma concentrations of celecoxib in patients taking celecoxib at a dosage from 200 mg to 400 mg . day -1 , ranging from 437 to 1087 ng·mL À1 (which equals 1.2-2.6 μM) (for a review see Sauter et al., 2008) . At this concentration, it seems possible that pre-activated TRPV3 currents may be enhanced by celecoxib in vivo. However, although dermatological side effects have been reported for coxibs, they not only occur under celecoxib therapy and are, therefore, not likely to be mediated by an increased activity of TRPV3 in keratinocytes. Moreover, apart from TRPV3, several other ion channels are modulated by celecoxib in a similar concentration range, which might further complicate linking physiological or pathophysiological effects of celecoxib treatment to the augmentation of TRPV3 activity in vitro and in vivo.
As celecoxib increased the open probability of single channels in isolated inside-out patches, we presume that no intracellular soluble factors are necessary for the observed potentiation of TRPV3. Moreover, as other coxibs tested in this study did affect TRPV3 gating to a much lesser degree, it seems unlikely that a COX-inhibition underlies the positive modulatory effect of celecoxib. We rather assume that celecoxib and deracoxib directly bind to TRPV3 channels, thereby increasing the NPo of the channel. With a logP value of about 4, coxibs are highly membrane permeable. We therefore cannot distinguish between an intra-or extracellular site of action. The exact mechanism by which celecoxib potentiates TRPV3 currents remains to be resolved. Interestingly, only heat-and 2-APB-activated TRPV3 channels were augmented by celecoxib, whereas carvacrol-induced currents were partially blocked by the drug. TRPV3 channels are allosterically modulated through different molecular mechanisms. Distinct regions within the TRPV3 protein, which are required for heat-, 2-APB-and camphor-induced TRPV3 activation, have been determined (Hu et al., 2009; Grandl et al., 2008; Sherkheli et al., 2013) , and tryptophane fluorescence quenching revealed that the binding of different ligands causes distinct conformational changes of the TRPV3 protein (Billen et al., 2015) . The specific manner of celecoxib modulation, for example, potentiation or inhibition, might therefore depend on the conformation of the TRPV3 channel after binding of the respective ligand or after a heat stimulus.
